Sofie Qiao News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sofie qiao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sofie Qiao Today - Breaking & Trending Today
/PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,. ....
/PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,. ....
/PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,. ....
Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, closed a $30m Series C financing. The round was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace. The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP. Led by Sofie Qiao, Ph.D., President and Chief Executive Officer, Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need. . ....
Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway News provided by Share this article Share this article SAN MATEO, Calif., Dec. 16, 2020 /PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Series C financing. The company anticipates advancing its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP. The Series C financing was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. With the financing, Dr. Norman Zhou of Boxer Capital has joined the board of directors at Vivace. ....